Akebia Therapeutics (AKBA) News
NASDAQ: AKBAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.3855-0.0368 (-8.71%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AKBA news summary
We found 8 recent headlines mentioning Akebia Therapeutics (AKBA): 3 in the past week and 8 in the past 30 days, most often from GlobeNewswire, Nasdaq. AKBA is making an outsized move today, down 8.71% at $0.3855, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent", was published by GlobeNewswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Akebia Therapeutics headlines
- Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional PatentNew patent with term until 2043 further strengthens patent portfolioGlobeNewswire
- Akebia Therapeutics, Inc. Enters into $140.0 million Senior Secured Term Loan FacilityAkebia Therapeutics, Inc. entered into a Loan and Security Agreement on November 12, 2026, providing for a senior secured term loan facility in the aggregate principal amount of up to $140.0 million.…Nasdaq
- Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 MillionInitial $60 million tranche fully funded, proceeds of which were used to fully repay $55 million BlackRock loan facilityGlobeNewswire
- Akebia (AKBA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Akebia Therapeutics Reports Third Quarter 2026 Financial ResultsAkebia Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026. Total revenues decreased to $36.9 million from $58.8 million in the third quarter of 2025,…Nasdaq
- Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsPatients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025GlobeNewswire
- U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney WeekVadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful…GlobeNewswire
- Akebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency NoticeOn October 21, 2026, Akebia Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market. The notice was issued because, for the last 30…Nasdaq